Jean-Marc Ferrero
A5032686530- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Prostate Cancer Treatment and Research
- Cancer Genomics and Diagnostics
- Renal cell carcinoma treatment
- Colorectal Cancer Treatments and Studies
- Breast Lesions and Carcinomas
- Radiopharmaceutical Chemistry and Applications
- Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
- Cancer Cells and Metastasis
- Prostate Cancer Diagnosis and Treatment
- BRCA gene mutations in cancer
- Peptidase Inhibition and Analysis
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Research Studies
- Renal and related cancers
- Cancer, Lipids, and Metabolism
- Advanced Radiotherapy Techniques
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Estrogen and related hormone effects
- Multiple and Secondary Primary Cancers
Centre Antoine Lacassagne
2015-2024
Centre François Baclesse
2006-2023
Université Côte d'Azur
2010-2020
Hospital Universitario Fundación Alcorcón
2020
Centre Méditerranéen de Médecine Moléculaire
2020
Hospital Universitario Reina Sofía
2018
Cancer Research Center
2014
Centre Léon Bérard
2012
Hôpital Lyon Sud
2012
Institut Jean Godinot
2009-2012
In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy pertuzumab, trastuzumab, and docetaxel, as compared placebo, docetaxel. Overall pertuzumab in an interim analysis without the median being reached. We report final prespecified overall results a follow-up of 50 months.We randomly assigned who had not received previous chemotherapy or anti-HER2 their...
Cross-talk between signal transduction pathways likely contributes to hormone resistance in metastatic breast cancer (mBC). Everolimus, an oral inhibitor of the mammalian target rapamycin, has restored sensitivity endocrine-resistance models and shown anticancer activity early-phase mBC clinical trials. This analysis evaluated efficacy safety everolimus combination with tamoxifen patients resistant aromatase inhibitors (AIs).This open-label, phase II study randomly assigned postmenopausal...
The PACS 01 trial compared six cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) with a sequential regimen three FEC followed by docetaxel (FEC-D) as adjuvant treatment for women node-positive early breast cancer.Between June 1997 March 2000, 1,999 patients operable cancer were randomly assigned to either every 21 days cycles, or docetaxel, both given days. Hormone-receptor-positive received tamoxifen 5 years after chemotherapy. primary end point was 5-year disease-free survival...
Purpose This multinational, double-blind, randomized, placebo-controlled, phase III trial assessed the efficacy and tolerability of oral platinum analog satraplatin in patients with metastatic castrate-refractory prostate cancer (CRPC) experiencing progression after one prior chemotherapy regimen. Patients Methods Nine hundred fifty were randomly assigned (2:1) to receive (n = 635) 80 mg/m 2 on days 1 5 a 35-day cycle prednisone mg twice daily or placebo 315) daily. Primary end points...
PURPOSE The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in triple-negative breast cancer (TNBC). AKT inhibitor capivasertib has shown preclinical activity TNBC models, and drug sensitivity been associated with activation of PI3K or and/or deletions PTEN. PAKT trial was designed to evaluate the safety efficacy adding paclitaxel as first-line therapy for TNBC. PATIENTS AND METHODS This double-blind, placebo-controlled, randomized phase II recruited women...
The recurrence score based on the 21-gene breast-cancer assay has been clinically useful in predicting a chemotherapy benefit hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary lymph-node-negative breast cancer. In women with positive lymph-node disease, role of respect to adjuvant is unclear.In prospective trial, we randomly assigned HER2-negative cancer, one three lymph nodes, and 25 or lower (scores range from 0 100, higher scores indicating...
ERRB2 (formerly HER2)-positive advanced breast cancer (ABC) remains typically incurable with optimal treatment undefined in later lines of therapy. The chimeric antibody margetuximab shares ERBB2 specificity trastuzumab but incorporates an engineered Fc region to increase immune activation.To compare the clinical efficacy vs trastuzumab, each chemotherapy, patients pretreated ERBB2-positive ABC.The SOPHIA phase 3 randomized open-label trial plus chemotherapy enrolled 536 from August 26,...
BackgroundAnti-HER2 therapies are associated with a risk of increased cardiac toxicity, particularly when part anthracycline-containing regimens. We report safety pertuzumab, trastuzumab, and chemotherapy in the neoadjuvant treatment HER2-positive early breast cancer.Patients methodsBERENICE (NCT02132949) is nonrandomized, phase II, open-label, multicenter, multinational study patients normal function. In period, cohort A received four cycles dose-dense doxorubicin cyclophosphamide, then 12...
To assess pertuzumab plus trastuzumab and an aromatase inhibitor (AI) in patients with human epidermal growth factor receptor 2 (HER2)-positive hormone receptor-positive metastatic/locally advanced breast cancer (MBC/LABC).The PERTAIN trial (NCT01491737) is ongoing randomized, open-label, multicenter-80 sites eight countries-phase II trial. Patients have HER2-positive, MBC/LABC no prior systemic therapy the exception of endocrine. Random assignment was 1:1 to intravenous (840 mg loading dose...
This multicenter, randomized, open-label phase III trial (planned enrollment: 700 patients) was conducted to test the hypothesis that single-agent sunitinib improves progression-free survival (PFS) compared with capecitabine as treatment for advanced breast cancer (ABC). Patients HER2-negative ABC recurred after anthracycline and taxane therapy were randomized (1:1) 37.5 mg/day or 1,250 mg/m(2) (1,000 in patients >65 years) BID on days 1-14 q3w. The independent data-monitoring committee...
Abstract HER2-positive breast cancer has long proven to be a clinically distinct class of cancers for which several targeted therapies are now available. However, resistance the treatment associated with specific gene expressions or mutations been observed, revealing underlying diversity these cancers. Therefore, understanding full extent disease heterogeneity still remains challenging. Here we carry out an in-depth genomic characterization 64 tumour genomes that exhibit four subgroups,...